UK charity hails Alzheimer’s drug Donanemab milestone
London, Jul 17 (PTI) A UK-based charity on Monday welcomed promising preliminary results from a trial of Alzheimer’s drug Donanemab which seems to slow down brain decline.
Alzheimer’s Research UK said the full results made public at the Alzheimer’s Association International Conference in Amsterdam by the pharmaceutical company Eli Lilly, which manufactures the drug, confirm that Donanemab was able to slow clinical decline by 35 per cent in people with early Alzheimer’s whose brain scans showed low or medium levels of a protein called Tau.
However, it had no effect on people with high Tau levels. Alzheimer’s Research UK’s Executive Director of Research & Partnerships, Dr Susan Kohlhaas, described the results as “another milestone” that confirmed, “the outlook for dementia and its impact on people and society is finally changing
